GNF-2
|
|
- CAS-Nr.
- 778270-11-4
- Englisch Name:
- GNF-2
- Synonyma:
- GNF-2;CS-569;GNF2;GNF 2;GNF 2, >=98%;GNF-2 USP/EP/BP;Bcr-abl Inhibitor;Bcr-abl Inhibitor - CAS 778270-11-4 - Calbiochem;3-(6-(4-(TRIFLUOROMETHOXY)PHENYLAMINO)PYRIMIDIN-4-YL)BENZAMIDE;3-[6-[[4-(Trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzamide;Benzamide, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-
- CBNumber:
- CB4973102
- Summenformel:
- C18H13F3N4O2
- Molgewicht:
- 374.32
- MOL-Datei:
- 778270-11-4.mol
|
GNF-2 Eigenschaften
- storage temp.
- 2-8°C
- L?slichkeit
- H2O: <2mg/mL
- Aggregatzustand
- White solid
- Farbe
- off-white
GNF-2 Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
GNF-2 is an allosteric inhibitor of Bcr-Abl (IC
50 = 267 nM). It is selective for Bcr-Abl over c-Abl and a panel of 63 additional kinases at 10 μM. It inhibits proliferation of Ba/F3 cells (IC
50 = 138 nM). GNF-2 (10 μM) reduces viral titers in Vero cells infected with infectious bronchitis virus (IBV), a coronavirus,
via inhibition of IBV surface glycoprotein-induced syncytia formation and virus-cell fusion. It inhibits LPS-induced production of nitric oxide (NO) and TNF-α in BV-2 microglia when used at concentrations of 10 and 20 μM. GNF-2 (1 and 10 mg/kg) reduces paw edema and increases the latency to paw withdrawal in a mouse model of inflammatory pain induced by complete Freund’s adjuvant (CFA). It also decreases mechanical and thermal hyperalgesia in a mouse model of diabetic neuropathy induced by streptozotocin (STZ; ).
Verwenden
Bcr-abl Inhibitor is an inhibitor of c-Abl and Bcr-abl activity. It is a COVID19-related research product.
Allgemeine Beschreibung
A cell-permeable and reverisble pyrimidine compound that binds to the c-abl myristoyl binding pocket and acts as an allosteric, non-ATP-competitive inhibitor of cellular Bcr-abl activity and Bcr-abl-dependent cellular functions. Exhibits little inhibitory effect against a panel of 63 kinases even at concentration as high as 10 μM. Exhibits potent and selective antiproliferative activity toward Bcr-abl-expressing cells (IC
50 = 138 nM, 194 nM, 268 nM and 273 nM in Ba/F3.p210, Ba/F3.p
185Y253H, SUP-B15 and Ba/F3.p
210E255V, and K562, respectively). Brij-35 is reported to mask the inhibitory effect of GNF-2 in cell-free c-abl and Bcr-abl kinase assays.
GNF-2 Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
GNF-2 Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 131)Lieferanten
778270-11-4()Verwandte Suche:
- 3-[6-[[4-(Trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzamide GNF-2
- GNF-2 3-[6-[[4-(Trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzamide
- GNF 2, >=98%
- 3-(6-(4-(TRIFLUOROMETHOXY)PHENYLAMINO)PYRIMIDIN-4-YL)BENZAMIDE
- Benzamide, 3-[6-[[4-(trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]-
- GNF-2
- Bcr-abl Inhibitor
- 3-[6-[[4-(Trifluoromethoxy)phenyl]amino]-4-pyrimidinyl]benzamide
- Bcr-abl Inhibitor - CAS 778270-11-4 - Calbiochem
- CS-569
- GNF2;GNF 2
- GNF-2 USP/EP/BP
- SARS coronavirus,GNF-2,allosteric,GNF 2,non-ATP competitive inhibitor,Ba/F3.p185Y253H,Bcr-Abl,Ba/F3.p210E255V,SARS-CoV,Ba/F3.p210,bone erosion,Inhibitor,inhibit
- 778270-11-4
- C18H13F3N4O2
- Inhibitors